Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.

Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS.

Cancer Immunol Res. 2019 Oct 28. pii: canimm.0793.2018. doi: 10.1158/2326-6066.CIR-18-0793. [Epub ahead of print]

PMID:
31658994
2.

Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.

Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33525-7. doi: 10.1016/j.jtho.2019.10.001. [Epub ahead of print]

PMID:
31605794
3.

High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.

Buetow KH, Meador LR, Menon H, Lu YK, Brill J, Cui H, Roe DJ, DiCaudo DJ, Hastings KT.

J Immunol. 2019 Nov 15;203(10):2577-2587. doi: 10.4049/jimmunol.1900476. Epub 2019 Oct 7.

PMID:
31591149
4.

Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.

Caetano MS, Younes AI, Barsoumian HB, Quigley M, Menon H, Gao C, Spires T, Reilly TP, Cadena AP, Cushman TR, Schoenhals JE, Li A, Nguyen QN, Cortez MA, Welsh JW.

Clin Cancer Res. 2019 Sep 20. doi: 10.1158/1078-0432.CCR-19-0795. [Epub ahead of print]

PMID:
31540976
5.

Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.

Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW.

JAMA Oncol. 2019 Sep 17. doi: 10.1001/jamaoncol.2019.2809. [Epub ahead of print]

PMID:
31529018
6.

Complications and adverse events of plaque brachytherapy for ocular melanoma.

Peddada KV, Sangani R, Menon H, Verma V.

J Contemp Brachytherapy. 2019 Aug;11(4):392-397. doi: 10.5114/jcb.2019.87407. Epub 2019 Aug 29.

7.

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.

Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW.

J Immunother Cancer. 2019 Sep 4;7(1):237. doi: 10.1186/s40425-019-0718-6.

8.

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context.

Patkar N, Kakirde C, Bhanshe P, Joshi S, Chaudhary S, Badrinath Y, Ghoghale S, Deshpande N, Kadechkar S, Chatterjee G, Kannan S, Shetty D, Gokarn A, Punatkar S, Bonda A, Nayak L, Jain H, Bagal B, Menon H, Sengar M, Khizer SH, Khattry N, Tembhare P, Gujral S, Subramanian P.

Front Oncol. 2019 Jun 13;9:450. doi: 10.3389/fonc.2019.00450. eCollection 2019.

9.

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab.

Bloom BC, Augustyn A, Pezzi TA, Menon H, Mayo LL, Shah SJ, Schwartz DL, Chmura SJ, Johnson FM, Welsh JW, Chun SG.

Front Oncol. 2019 Apr 5;9:223. doi: 10.3389/fonc.2019.00223. eCollection 2019.

10.

IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Li A, Barsoumian HB, Schoenhals JE, Caetano MS, Wang X, Menon H, Valdecanas DR, Niknam S, Younes AI, Cortez MA, Welsh JW.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):903-912. doi: 10.1016/j.ijrobp.2019.03.022. Epub 2019 Mar 21.

PMID:
30905636
11.

Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment.

Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar C, Selek U, Chun SG, Chang JY, Barsoumian HB, Nguyen QN, Altan M, Cortez MA, Hahn SM, Welsh JW.

Front Immunol. 2019 Feb 15;10:193. doi: 10.3389/fimmu.2019.00193. eCollection 2019. Review.

12.

Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia.

Patkar N, Kodgule R, Kakirde C, Raval G, Bhanshe P, Joshi S, Chaudhary S, Badrinath Y, Ghoghale S, Kadechkar S, Khizer SH, Kannan S, Shetty D, Gokarn A, Punatkar S, Jain H, Bagal B, Menon H, Sengar M, Khattry N, Tembhare P, Subramanian P, Gujral S.

Oncotarget. 2019 Jan 15;10(5):617. doi: 10.18632/oncotarget.26610. eCollection 2019 Jan 15.

13.

Role of miRNAs in immune responses and immunotherapy in cancer.

Cortez MA, Anfossi S, Ramapriyan R, Menon H, Atalar SC, Aliru M, Welsh J, Calin GA.

Genes Chromosomes Cancer. 2019 Apr;58(4):244-253. doi: 10.1002/gcc.22725. Review.

PMID:
30578699
14.

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia.

Patkar N, Kodgule R, Kakirde C, Raval G, Bhanshe P, Joshi S, Chaudhary S, Badrinath Y, Ghoghale S, Kadechkar S, Khizer SH, Kannan S, Shetty D, Gokarn A, Punatkar S, Jain H, Bagal B, Menon H, Sengar M, Khattry N, Tembhare P, Subramanian P, Gujral S.

Oncotarget. 2018 Nov 27;9(93):36613-36624. doi: 10.18632/oncotarget.26400. eCollection 2018 Nov 27. Erratum in: Oncotarget. 2019 Jan 15;10(5):617.

15.

Altered cancer metabolism in mechanisms of immunotherapy resistance.

Ramapriyan R, Caetano MS, Barsoumian HB, Mafra ACP, Zambalde EP, Menon H, Tsouko E, Welsh JW, Cortez MA.

Pharmacol Ther. 2019 Mar;195:162-171. doi: 10.1016/j.pharmthera.2018.11.004. Epub 2018 Nov 12. Review.

PMID:
30439456
16.

Cost reduction associated with heparin-induced thrombocytopenia panel ordering for enoxaparin versus heparin for prophylactic and therapeutic use: A retrospective analysis in a community hospital setting.

Menon H, Pillai A, Aussenberg-Rodriguez J, Ambrose J, Youssef I, Griffiths EA, Al Ustwani O.

Avicenna J Med. 2018 Oct-Dec;8(4):133-138. doi: 10.4103/ajm.AJM_78_18.

17.

BRAFV600E mutation in hairy cell leukemia: A single-center experience.

Bibi A, Java S, Chaudhary S, Joshi S, Mascerhenas R, Rabade N, Tembhare P, Subramanian PG, Gujral S, Menon H, Khattry N, Sengar M, Bagal B, Jain H, Patkar N.

Indian J Pathol Microbiol. 2018 Oct-Dec;61(4):532-536. doi: 10.4103/IJPM.IJPM_484_16.

18.

Postoperative chemoradiotherapy versus radiotherapy alone for elderly cervical cancer patients with positive margins, lymph nodes, or parametrial invasion.

Cushman TR, Haque W, Menon H, Rusthoven CG, Butler EB, Teh BS, Verma V.

J Gynecol Oncol. 2018 Nov;29(6):e97. doi: 10.3802/jgo.2018.29.e97.

19.

Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit.

Khattry N, Laskar S, Sengar M, Rangarajan V, Shet T, Subramanian PG, Epari S, Bagal B, Goda JS, Agarwal A, Jain H, Tembhare P, Patkar N, Khanna N, Punatar S, Gokarn A, Shetty D, Jain H, Bonda A, Gota V, Hasan S, Kode J, Dutt S, Kulkarni S, Shetty N, Sable N, Deodhar J, Jadhav S, Pawaskar P, Mathew L, Menon H, Nair R, Kannan S, Chiplunkar S, Gujral S.

Indian J Cancer. 2018 Jan-Mar;55(1):9-15. doi: 10.4103/ijc.IJC_656_17.

20.

Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group.

Nair R, Kakroo A, Bapna A, Gogia A, Vora A, Pathak A, Korula A, Chakrapani A, Doval D, Prakash G, Biswas G, Menon H, Bhattacharya M, Chandy M, Parihar M, Vamshi Krishna M, Arora N, Gadhyalpatil N, Malhotra P, Narayanan P, Nair R, Basu R, Shah S, Bhave S, Bondarde S, Bhartiya S, Nityanand S, Gujral S, Tilak TVS, Radhakrishnan V.

Indian J Hematol Blood Transfus. 2018 Jul;34(3):398-421. doi: 10.1007/s12288-018-0991-4. Epub 2018 Aug 3. Review.

21.

Demographic profile, clinicopathological spectrum, and treatment outcomes of primary central nervous system tumors: Retrospective audit from an academic neuro-oncology unit.

Gupta T, Epari S, Moiyadi A, Shetty P, Goda JS, Krishnatry R, Chinnaswamy G, Vora T, Menon H, Patil V, Sahay A, Bano N, Jalali R.

Indian J Cancer. 2017 Oct-Dec;54(4):594-600. doi: 10.4103/ijc.IJC_543_17.

22.

Applicability of 2008 World Health Organization classification system of hematolymphoid neoplasms: Learning experiences.

Modkharkar S, Navale P, Amare PK, Chougule A, Patkar N, Tembhare P, Menon H, Sengar M, Khattry N, Banavali S, Arora B, Narula G, Laskar S, Khanna N, Muckaden MA, Rangarajan V, Agrawal A, Shet T, Epari S, Subramanian PG, Gujral S.

Indian J Pathol Microbiol. 2018 Jan-Mar;61(1):58-65. doi: 10.4103/IJPM.IJPM_56_17.

23.

Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.

Agrawal K, Shet T, Sridhar E, Dhende S, Sengar M, Arora B, Laskar S, Gujral S, Menon H, Banavali S.

Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):533-540. doi: 10.4103/IJPM.IJPM_778_15.

24.

Achieving scale rapidly in public health: Applying business management principles to scale up an HIV prevention program in India.

Sgaier SK, Ramakrishnan A, Wadhwani A, Bhalla A, Menon H, Baer J, Alexander A.

Healthc (Amst). 2018 Sep;6(3):210-217. doi: 10.1016/j.hjdsi.2017.09.002. Epub 2017 Sep 21.

25.

Non-adherence to CML therapy and its clinical implications in India.

Menon H.

Natl Med J India. 2017 May-Jun;30(3):142-147. Review.

26.

A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.

Glisson B, Besse B, Dols MC, Dubey S, Schupp M, Jain R, Jiang Y, Menon H, Nackaerts K, Orlov S, Paz-Ares L, Ramlau R, Tang R, Zhang Y, Zhu M.

Clin Lung Cancer. 2017 Nov;18(6):615-625.e8. doi: 10.1016/j.cllc.2017.05.007. Epub 2017 May 10.

PMID:
28601388
27.

Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.

Kadam Amare PS, Jain H, Nikalje S, Sengar M, Menon H, Inamdar N, Subramanian PG, Gujral S, Shet T, Epari S, Nair R.

Indian J Med Res. 2016 Oct;144(4):536-543. doi: 10.4103/0971-5916.200890.

28.

Immunogenetics of chronic lymphocytic leukemia.

Patkar N, Rabade N, Kadam PA, Mishra F, Muranjan A, Tembhare P, Chaudhary S, Joshi S, Jain H, Dangi U, Bagal B, Khattry N, Menon H, Gujral S, Sengar M, Subramanian PG.

Indian J Pathol Microbiol. 2017 Jan-Mar;60(1):38-42. doi: 10.4103/0377-4929.200051.

29.

Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference.

Yanamandra U, Khattry N, Kumar S, Raje N, Jain A, Jagannath S, Menon H, Kumar L, Varma N, Varma S, Saikia T, Malhotra P; for IMAGe Group.

Indian J Hematol Blood Transfus. 2017 Mar;33(1):15-21. doi: 10.1007/s12288-016-0773-9. Epub 2017 Jan 2. Review.

30.

Outcomes of Short Segment Posterior Instrumentation in Unstable Thoracolumbar Fractures.

Gajjar SH, Menon HJ, Chaudhari N, Chaudhari V.

J Clin Diagn Res. 2016 Nov;10(11):RC04-RC08. doi: 10.7860/JCDR/2016/23133.8825. Epub 2016 Nov 1.

31.

Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.

Gota V, Karanam A, Rath S, Yadav A, Tembhare P, Subramanian P, Sengar M, Nair R, Menon H.

Cancer Chemother Pharmacol. 2016 Aug;78(2):353-9. doi: 10.1007/s00280-016-3083-x. Epub 2016 Jun 21.

PMID:
27329361
32.

Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.

Patkar N, Ghodke K, Joshi S, Chaudhary S, Mascerhenas R, Dusseja S, Mahadik S, Gaware S, Tembhare P, Gujral S, Kabre S, Kadam-Amare P, Jain H, Dangi U, Bagal B, Khattry N, Sengar M, Arora B, Narula G, Banavali S, Menon H, Subramanian PG.

Leuk Lymphoma. 2016 Nov;57(11):2653-60. doi: 10.3109/10428194.2016.1157868. Epub 2016 Mar 21.

PMID:
26999421
33.

Mediastinal Gray Zone Lymphoma: A Wider Category Than We Think?

Verma A, Shet T, Epari S, Gupta M, Gujral S, Khanna N, Laskar S, Sengar M, Arora B, Menon H, Banavali S.

Int J Surg Pathol. 2016 Aug;24(5):382-93. doi: 10.1177/1066896916635816. Epub 2016 Mar 7.

PMID:
26957476
34.

ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries.

Nampoothiri SS, Menon HV, Das D, Krishnamurthy RG.

Curr Drug Targets. 2016;17(7):800-10. Review.

PMID:
25981603
35.

A retrospective study of correlation of morphologic patterns, MIB1 proliferation index, and survival analysis in 134 cases of plasmacytoma.

Ghodke K, Shet T, Epari S, Sengar M, Menon H, Gujral S.

Ann Diagn Pathol. 2015 Jun;19(3):117-23. doi: 10.1016/j.anndiagpath.2015.02.006. Epub 2015 Mar 5.

PMID:
25842207
36.

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J, Seth T, Gayathri K, Menon H, Subramanian PG, Sharma A, Bhattacharyya M, Mehta J, Vaid AK, Shah S, Aggarwal S, Gogoi PK, Nair R, Agarwal U, Varma S, Prasad SV, Manipadam MT.

Indian J Med Paediatr Oncol. 2015 Jan-Mar;36(1):3-16. doi: 10.4103/0971-5851.151770.

37.

Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.

Jain H, Sengar M, Nair R, Menon H, Laskar S, Shet T, Gujral S, Sridhar E.

J Postgrad Med. 2015 Apr-Jun;61(2):88-91. doi: 10.4103/0022-3859.150446.

38.

Syntaxin1A-mediated Resistance and Hypersensitivity to Isoflurane in Drosophila melanogaster.

Zalucki OH, Menon H, Kottler B, Faville R, Day R, Bademosi AT, Lavidis N, Karunanithi S, van Swinderen B.

Anesthesiology. 2015 May;122(5):1060-74. doi: 10.1097/ALN.0000000000000629.

PMID:
25738637
39.

A simplified scoring system to document variant patterns in nodular lymphocyte predominant Hodgkin lymphoma.

Shet T, Panjwani P, Epari S, Sengar M, Prasad M, Arora B, Laskar S, Gujral S, Menon H, Banavali S.

Leuk Lymphoma. 2015 Jun;56(6):1651-8. doi: 10.3109/10428194.2014.961013. Epub 2014 Nov 20.

PMID:
25248885
40.

MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.

Patkar N, Subramanian PG, Deshpande P, Ghodke K, Tembhare P, Mascarenhas R, Muranjan A, Chaudhary S, Bagal B, Gujral S, Sengar M, Menon H.

Leuk Lymphoma. 2015 Feb;56(2):420-5. doi: 10.3109/10428194.2014.924123. Epub 2014 Aug 4.

PMID:
24828863
41.

Dengue fever as a cause of febrile neutropenia in adult acute lymphoblastic leukemia: a single center experience.

Jain H, Sengar M, Menon H, Dangi U, Biswas S, Chandrakanth MV.

Hematol Oncol Stem Cell Ther. 2014 Sep;7(3):125-6. doi: 10.1016/j.hemonc.2014.04.002. Epub 2014 Apr 30. No abstract available.

42.

Blastic plasmacytoid dendritic cell neoplasm: a rare subtype of myeloid leukemia.

Jain H, Sengar M, Menon H, Chandrakanth MV.

Hematol Oncol Stem Cell Ther. 2014 Jun;7(2):97-8. doi: 10.1016/j.hemonc.2014.03.003. Epub 2014 Apr 29. No abstract available.

43.

Bone marrow involvement in nodular lymphocyte predominant Hodgkin lymphoma occurs in tumors with a variant pattern.

Panjwani P, Epari S, Sengar M, Laskar S, Menon H, Shet T.

Leuk Lymphoma. 2015 Jan;56(1):236-8. doi: 10.3109/10428194.2014.916802. Epub 2014 Jun 27. No abstract available.

PMID:
24766468
44.

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW.

Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4.

45.

Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis.

Roy PS, John S, Karankal S, Kannan S, Pawaskar P, Gawande J, Bagal B, Khattry N, Sengar M, Menon H, Gujral S, Nair R.

Indian J Med Paediatr Oncol. 2013 Oct;34(4):292-8. doi: 10.4103/0971-5851.125248.

46.

Extranodal natural killer/T cell lymphomas with extranasal disease in non-endemic regions are disseminated or have nasal primary: a study of 84 cases from India.

Shet T, Suryawanshi P, Epari S, Sengar M, Rangarajan V, Menon H, Laskar S.

Leuk Lymphoma. 2014 Dec;55(12):2748-53. doi: 10.3109/10428194.2014.894188. Epub 2014 Apr 3.

PMID:
24597982
47.

Therapeutic drug monitoring for imatinib: Current status and Indian experience.

Arora B, Gota V, Menon H, Sengar M, Nair R, Patial P, Banavali SD.

Indian J Med Paediatr Oncol. 2013 Jul;34(3):224-8. doi: 10.4103/0971-5851.123752.

48.

Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcome.

Menon H.

South Asian J Cancer. 2013 Jan;2(1):38-43. doi: 10.4103/2278-330X.105893. Review.

49.

Nodular lymphocyte predominant Hodgkin lymphoma and diphenylhydantoin: report of a case and review of the literature.

Sharma S, Menon H, Sengar M, Gujral S.

Indian J Pathol Microbiol. 2013 Oct-Dec;56(4):440-2. doi: 10.4103/0377-4929.125364. Review.

50.

Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?

Laskar S, Kumar DP, Khanna N, Menon H, Sengar M, Arora B, Gujral S, Shet T, Sridhar E, Rangarajan V, Muckaden MA, Nair R, Banavali S.

Leuk Lymphoma. 2014 Oct;55(10):2356-61. doi: 10.3109/10428194.2013.871631. Epub 2014 Mar 7.

PMID:
24354681

Supplemental Content

Support Center